Pages that link to "Q38709406"
Jump to navigation
Jump to search
The following pages link to GLP-1 Agonists and Blood Pressure: A Review of the Evidence. (Q38709406):
Displaying 11 items.
- Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies (Q38912469) (← links)
- Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus (Q38989517) (← links)
- Gastrointestinal Tract: a Promising Target for the Management of Hypertension (Q39204264) (← links)
- Bariatric Surgery and Hypertension (Q47849996) (← links)
- Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol. (Q55215230) (← links)
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial (Q57026289) (← links)
- Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function (Q59812434) (← links)
- Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats (Q89472784) (← links)
- Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures (Q90503100) (← links)
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (Q92125371) (← links)
- Use of real-world data to emulate a clinical trial and support regulatory decision-making: assessing the impact of temporality, comparator choice and methods of adjustment (Q98243091) (← links)